ARCH Venture Management, LLC — 13F Holdings & Portfolio
CIK 1274403 · latest 13F-HR filed 2026-08-14
ARCH Venture Management, LLC manages $1.10B in 13F-reported U.S. long-equity assets across 12 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PBLS (15.95%), BEAM (14.16%), RAPP (14.12%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions and exited 1; 6 existing positions rose in reported value and 2 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 99.3%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 30, 2026.
SUITE 1025
CHICAGO, IL 60631-2176
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| BUROW, KRISTINA, MARIE Control | MANAGING DIRECTOR, VICE PRESIDENT, AND SHAREHOLDER since Sep 2020 | 10–25% | Individual |
| Berns, Paul, Louis Control | MANAGING DIRECTOR since Jan 2024 | Less than 5% | Individual |
| CRANDELL, KEITH, LAWRENCE Control | MANAGING DIRECTOR, PRESIDENT, SECRETARY AND SHAREHOLDER since Jun 2001 | 25–50% | Individual |
| NELSEN, ROBERT, TAYLOR Control | MANAGING DIRECTOR, CEO, AND SHAREHOLDER since Jun 2001 | 25–50% | Individual |
| BYBEE, CLINTON, WHITEWOOD | MANAGING DIRECTOR since Sep 2020 | Less than 5% | Individual |
| GILLIS, STEVEN, NMN | MANAGING DIRECTOR since Oct 2007 | Less than 5% | Individual |
| MCDONNELL, MARK, ANDREW | MANAGING DIRECTOR, CFO AND CAO since Nov 2011 | Less than 5% | Individual |
Ownership & leadership changes · 4 filings with changes since Mar 30, 2012
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- AddedBerns, Paul, Louis · MANAGING DIRECTOR · Less than 5% · control person
- No longer listedTHURK, PAUL, STEVEN · MANAGING DIRECTOR · Less than 5% · listed since Nov 2011
- ChangedBUROW, KRISTINA, MARIE · title MANAGING DIRECTOR → MANAGING DIRECTOR, VICE PRESIDENT, AND SHAREHOLDER; ownership Less than 5% → 10–25%; now a control person
- ChangedBYBEE, CLINTON, WHITEWOOD · title MANAGING DIRECTOR AND SHAREHOLDER → MANAGING DIRECTOR; ownership 25–50% → Less than 5%; no longer a control person
- ChangedCRANDELL, KEITH, LAWRENCE · title MANAGING DIRECTOR, PRESIDENT AND SHAREHOLDER → MANAGING DIRECTOR, PRESIDENT, SECRETARY AND SHAREHOLDER
- ChangedNELSEN, ROBERT, TAYLOR · title MANAGING DIRECTOR, VICE PRESIDENT, SECRETARY AND SHAREHOLDER → MANAGING DIRECTOR, CEO, AND SHAREHOLDER
- No longer listedLAZARUS, STEVEN, NMN · MANAGING DIRECTOR, PRESIDENT, TREASURER AND SHAREHOLDER · 25–50% · control person · listed since Jun 2001
- ChangedCRANDELL, KEITH, LAWRENCE · title MANAGING DIRECTOR, VICE PRESIDENT, SECRETARY AND SHAREHOLDER → MANAGING DIRECTOR, PRESIDENT AND SHAREHOLDER
- ChangedNELSEN, ROBERT, TAYLOR · title MANAGING DIRECTOR, ASSISTANT SECRETARY AND SHAREHOLDER → MANAGING DIRECTOR, VICE PRESIDENT, SECRETARY AND SHAREHOLDER
- ListedBUROW, KRISTINA, MARIE · MANAGING DIRECTOR · Less than 5%
- ListedBYBEE, CLINTON, WHITEWOOD · MANAGING DIRECTOR AND SHAREHOLDER · 25–50% · control person
- ListedCRANDELL, KEITH, LAWRENCE · MANAGING DIRECTOR, VICE PRESIDENT, SECRETARY AND SHAREHOLDER · 25–50% · control person
- ListedGILLIS, STEVEN, NMN · MANAGING DIRECTOR · Less than 5%
- ListedLAZARUS, STEVEN, NMN · MANAGING DIRECTOR, PRESIDENT, TREASURER AND SHAREHOLDER · 25–50% · control person
- ListedMCDONNELL, MARK, ANDREW · MANAGING DIRECTOR, CFO AND CAO · Less than 5%
- ListedNELSEN, ROBERT, TAYLOR · MANAGING DIRECTOR, ASSISTANT SECRETARY AND SHAREHOLDER · 25–50% · control person
- ListedTHURK, PAUL, STEVEN · MANAGING DIRECTOR · Less than 5%
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- BEAM THERAPEUTICS INC$47.6M +44.0%
- RAPPORT THERAPEUTICS INC$38.7M +33.2%
- ERASCA INC$15.2M +13.2%
- VIR BIOTECHNOLOGY INC$13.6M +11.8%
- GENERATE BIOMEDICINES INC$8.5M +35.0%
New Positions
- PARABILIS MEDICINES INC$175.5M
- SEAPORT THERAPEUTICS INC$136.6M
- BOUNDLESS BIO INC$6.7M
ARCH Venture Management, LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PARABILIS MEDICINES INC | PBLS | 698955101 | $175.5M | 15.95% | 6,412,780 | SH |
| 2 | BEAM THERAPEUTICS INC | BEAM | 07373V105 | $155.8M | 14.16% | 4,540,132 | SH |
| 3 | RAPPORT THERAPEUTICS INC | RAPP | 75383L102 | $155.4M | 14.12% | 3,728,738 | SH |
| 4 | SEAPORT THERAPEUTICS INC | SPTX | 81221K108 | $136.6M | 12.42% | 6,294,951 | SH |
| 5 | ERASCA INC | ERAS | 29479A108 | $129.9M | 11.81% | 7,091,557 | SH |
| 6 | VIR BIOTECHNOLOGY INC | VIR | 92764N102 | $129.4M | 11.76% | 12,694,163 | SH |
| 7 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $123.0M | 11.18% | 4,120,053 | SH |
| 8 | LYELL IMMUNOPHARMA INC | LYEL | 55083R203 | $45.5M | 4.14% | 3,247,162 | SH |
| 9 | GENERATE BIOMEDICINES INC | GENB | 370920100 | $32.8M | 2.98% | 1,944,426 | SH |
| 10 | 10X GENOMICS INC | TXG | 88025U109 | $8.4M | 0.76% | 217,834 | SH |
| 11 | BOUNDLESS BIO INC | BOLD | 10170A100 | $6.7M | 0.61% | 2,694,095 | SH |
| 12 | GOSSAMER BIO INC | GOSS | 38341P102 | $1.3M | 0.12% | 8,055,916 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.10B | 12 | 0001012975-26-000794 |
| 2026-03-31 | 2026-05-15 | $677.1M | 10 | 0001012975-26-000461 |
| 2025-12-31 | 2026-02-17 | $651.7M | 9 | 0001012975-26-000153 |
| 2025-09-30 | 2025-11-14 | $492.4M | 9 | 0001012975-25-000787 |
8755 W. HIGGINS RD. #1025
CHICAGO, IL 60631